These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 34520034)
1. Adverse effects of regulation on buprenorphine prescribing and its impact on the treatment of opioid use disorder. Strickland DM; Sorboro J J Opioid Manag; 2021; 17(7):133-139. PubMed ID: 34520034 [TBL] [Abstract][Full Text] [Related]
2. Addressing buprenorphine bottlenecks in the context of MAT Act implementation: A shared responsibility. Ostrach B; Hill L; Carpenter D; Pollini R J Am Pharm Assoc (2003); 2023; 63(4):1044-1048. PubMed ID: 37149144 [TBL] [Abstract][Full Text] [Related]
3. Geographic and specialty distribution of US physicians trained to treat opioid use disorder. Rosenblatt RA; Andrilla CH; Catlin M; Larson EH Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888 [TBL] [Abstract][Full Text] [Related]
4. Medication-Assisted Treatment for Opioid Use Disorder in a Rural Family Medicine Practice. Deyo-Svendsen M; Cabrera Svendsen M; Walker J; Hodges A; Oldfather R; Mansukhani MP J Prim Care Community Health; 2020; 11():2150132720931720. PubMed ID: 32507023 [TBL] [Abstract][Full Text] [Related]
5. Eliminate the buprenorphine DEA X waiver: Justification using a policy analysis approach. Jones KF; O'Reilly Jacob M; Spetz J; Hailer L; Tierney M J Nurs Scholarsh; 2023 May; 55(3):655-664. PubMed ID: 36624606 [TBL] [Abstract][Full Text] [Related]
6. What the X? Understanding changes in buprenorphine prescribing regulation. Speight C J Am Assoc Nurse Pract; 2024 Mar; 36(3):147-150. PubMed ID: 37646580 [TBL] [Abstract][Full Text] [Related]
7. Medication Treatment of Opioid Use Disorder. Bell J; Strang J Biol Psychiatry; 2020 Jan; 87(1):82-88. PubMed ID: 31420089 [TBL] [Abstract][Full Text] [Related]
8. Medications for management of opioid use disorder. Koehl JL; Zimmerman DE; Bridgeman PJ Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869 [TBL] [Abstract][Full Text] [Related]
9. The US Opioid Crisis: Current Federal and State Legal Issues. Soelberg CD; Brown RE; Du Vivier D; Meyer JE; Ramachandran BK Anesth Analg; 2017 Nov; 125(5):1675-1681. PubMed ID: 29049113 [TBL] [Abstract][Full Text] [Related]
10. From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States. Jaffe JH; O'Keeffe C Drug Alcohol Depend; 2003 May; 70(2 Suppl):S3-11. PubMed ID: 12738346 [TBL] [Abstract][Full Text] [Related]
11. Geographic Distribution of Providers With a DEA Waiver to Prescribe Buprenorphine for the Treatment of Opioid Use Disorder: A 5-Year Update. Andrilla CHA; Moore TE; Patterson DG; Larson EH J Rural Health; 2019 Jan; 35(1):108-112. PubMed ID: 29923637 [TBL] [Abstract][Full Text] [Related]
12. A Guide to Expanding the Use of Buprenorphine Beyond Standard Initiations for Opioid Use Disorder. Miller JC; Brooks MA; Wurzel KE; Cox EJ; Wurzel JF Drugs R D; 2023 Dec; 23(4):339-362. PubMed ID: 37938531 [TBL] [Abstract][Full Text] [Related]
13. Intravenous Misuse of Methadone, Buprenorphine and Buprenorphine-Naloxone in Patients Under Opioid Maintenance Treatment: A Cross-Sectional Multicentre Study. Lugoboni F; Zamboni L; Cibin M; Tamburin S; Eur Addict Res; 2019; 25(1):10-19. PubMed ID: 30625491 [TBL] [Abstract][Full Text] [Related]
14. Buprenorphine implants in medical treatment of opioid addiction. Chavoustie S; Frost M; Snyder O; Owen J; Darwish M; Dammerman R; Sanjurjo V Expert Rev Clin Pharmacol; 2017 Aug; 10(8):799-807. PubMed ID: 28571505 [TBL] [Abstract][Full Text] [Related]
15. Association between buprenorphine/naloxone and high-dose opioid analgesic prescribing in Kentucky, 2012-2017. Luu H; Slavova S; Freeman PR; Lofwall M; Browning S; Slade E; Bush H Drug Alcohol Depend; 2019 Dec; 205():107606. PubMed ID: 31606590 [TBL] [Abstract][Full Text] [Related]
16. Buprenorphine in the United States: Motives for abuse, misuse, and diversion. Chilcoat HD; Amick HR; Sherwood MR; Dunn KE J Subst Abuse Treat; 2019 Sep; 104():148-157. PubMed ID: 31370979 [TBL] [Abstract][Full Text] [Related]
17. Once-monthly subcutaneous buprenorphine (Sublocade) for opioid use disorder. Med Lett Drugs Ther; 2018 Feb; 60(1541):35-37. PubMed ID: 29485976 [No Abstract] [Full Text] [Related]
18. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre. Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243 [TBL] [Abstract][Full Text] [Related]
19. News Media Reporting On Medication Treatment For Opioid Use Disorder Amid The Opioid Epidemic. Kennedy-Hendricks A; Levin J; Stone E; McGinty EE; Gollust SE; Barry CL Health Aff (Millwood); 2019 Apr; 38(4):643-651. PubMed ID: 30933576 [TBL] [Abstract][Full Text] [Related]